KBC Group NV Purchases 3,857 Shares of Hologic, Inc. (NASDAQ:HOLX)

KBC Group NV grew its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 4.1% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 97,233 shares of the medical equipment provider's stock after acquiring an additional 3,857 shares during the quarter. KBC Group NV's holdings in Hologic were worth $6,006,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of HOLX. EverSource Wealth Advisors LLC lifted its position in Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after purchasing an additional 260 shares during the period. Smartleaf Asset Management LLC lifted its holdings in shares of Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after acquiring an additional 159 shares during the period. Smithfield Trust Co boosted its position in shares of Hologic by 160.0% during the 4th quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock valued at $45,000 after acquiring an additional 400 shares in the last quarter. Raiffeisen Bank International AG acquired a new stake in shares of Hologic during the 4th quarter valued at about $49,000. Finally, West Financial Advisors LLC bought a new stake in Hologic in the first quarter valued at about $50,000. Institutional investors and hedge funds own 94.73% of the company's stock.

Insider Buying and Selling at Hologic

In related news, Director Martin D. Madaus purchased 5,445 shares of Hologic stock in a transaction dated Wednesday, May 7th. The shares were acquired at an average cost of $55.24 per share, for a total transaction of $300,781.80. Following the transaction, the director directly owned 5,445 shares of the company's stock, valued at approximately $300,781.80. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 1.88% of the stock is currently owned by company insiders.

Hologic Trading Down 0.9%

Hologic stock traded down $0.57 during mid-day trading on Thursday, hitting $64.74. The stock had a trading volume of 1,233,581 shares, compared to its average volume of 2,373,435. The stock has a 50-day simple moving average of $60.58 and a two-hundred day simple moving average of $63.81. The company has a current ratio of 3.24, a quick ratio of 2.52 and a debt-to-equity ratio of 0.54. The stock has a market capitalization of $14.43 billion, a PE ratio of 27.31, a P/E/G ratio of 2.39 and a beta of 0.55. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 13.83% and a return on equity of 19.71%. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. During the same period in the prior year, the company posted $1.03 EPS. The company's revenue was down 1.2% compared to the same quarter last year. As a group, sell-side analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Analyst Ratings Changes

HOLX has been the topic of a number of recent research reports. Evercore ISI decreased their price objective on Hologic from $65.00 to $62.00 and set an "in-line" rating on the stock in a report on Friday, May 2nd. Royal Bank Of Canada decreased their price target on Hologic from $75.00 to $70.00 and set a "sector perform" rating on the stock in a research note on Friday, May 2nd. Wall Street Zen cut Hologic from a "buy" rating to a "hold" rating in a research report on Monday, May 5th. Morgan Stanley reduced their target price on shares of Hologic from $77.00 to $65.00 and set an "equal weight" rating on the stock in a research note on Monday, May 5th. Finally, Raymond James Financial reiterated an "outperform" rating and set a $71.00 target price (down previously from $90.00) on shares of Hologic in a research report on Friday, May 2nd. Twelve investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and an average target price of $77.42.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.